Cambridge Healthtech Institute’s 9th Annual

Higher-Throughput Protein Production and Characterization
( 蛋白質製造和表徵的高通量技術 )

Analyzing & Improving Processes


Part of the Process Technologies & Purification pipeline

In CHI’s Higher-Throughput Protein Production and Characterization conference, HTP is explored in the quest to develop methods that ensure quality and translate to large scale much more quickly and efficiently than in the past. Automation, robotics, and liquid handlers will be discussed, along with developing small-scale models and multi-scale models that shed light on bioproduction, particularly for continuous processing. Case studies will be presented that illustrate how leaders in the field are integrating HTP approaches to reduce the time and effort needed to successfully analyze proteins, fine tune processes, and develop new classes of biological products.

Final Agenda


7:45 am Registration and Morning Coffee

Generating Protein Libraries and Large Datasets with HTP

8:10 Organizer’s Welcome Remarks

Mary Ruberry, MA, Senior Conference Director, Cambridge Healthtech Institute

8:15 Chairperson’s Opening Remarks

Christopher Bahl, PhD, Head, Protein Design, Protein Design Laboratory, Institute for Protein Innovation



8:20 High-Throughput Generation of Protein Libraries for Early-Stage Development of Novel Therapeutics

Renaud Vincentelli, PhD, Head, High-Throughput Protein Production, Structural Biology Core, Architecture et Fonction des Macromolécules Biologiques (AFMB), UMR, CNRS – Aix-Marseille University

This presentation details the high-throughput E. coli protein production pipeline at the AFMB and its streamlining to generate exhaustive libraries of various protein families, including animal toxins and PDZ domains. The pipeline facilitates rapid expression screening, protein production, and sample quality control; thereby harnessing the potential of these large protein families for the development of novel therapeutics.

9:00 Platformization of Multi-Specific Protein Engineering III: Generating Large, Multiparametric Data Sets for Data Mining through End-to-End Automated High-Throughput Engineering Workflows

Birkenfeld_JoergJörg Birkenfeld, PhD, Section Head, High-Throughput Biologics, R&D Biologics Research/Protein Therapeutics, Sanofi-Aventis Deutschland GmbH

We recently established a novel, end-to-end automated process for the fast generation and characterization of very large panels of multi-specific variants (up to 10.000). Here we report on how we apply this high-throughput engineering platform for multiparametric optimization of next-generation protein therapeutics.

9:30 Extended Horizons of LabChip™ Microfluidic Characterization Platform for Biotherapeutic Screening and Quality Control

Meng_GuangnanGuangnan Meng, Product Manager, Microfluidics, PerkinElmer

The LabChip™ GXII Touch protein characterization system from PerkinElmer is a smart microfluidic platform for high throughput quantification and quality screening of protein molecules. With simple sample preparation setup, minimal sample volume consummation, and accurate and reliable measurements, it has been widely adopted into modern biotherapeutic screening and quality control processes. We will present our latest development of protein characterization assays, and discuss the new range and capabilities of the LabChip™ GXII Touch platform.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

High-Throughput Protein Production


11:00 PEPP: An Automated High-Throughput Protein Production Platform

Rue_SarahSarah Rue, PhD, Associate Director, Advanced Automation Technologies, Genomics Institute of the Novartis Research Foundation (GNF)

Recombinant protein expression and purification is critical to support biomedical research. Chinese hamster ovary (CHO) cells and Human Embryonic Kidney (HEK) cells are workhorse cell lines for protein production from mammalian cells.  GNF has developed a suite of automation and custom software to support transient protein production in CHO or HEK cells, stable pool establishment in CHO cells, the archive of cell banks, and protein purification.  Cells are handled in AutoFlasks™ on the system, and cell growth is monitored in a non-invasive manner daily using a custom Flask Density Reader.  An innovative new software Dashboard to help the operator manage projects and execute processes will be described, as will new hardware to enable a magnetic bead-based purification workflow.  This platform enables cost-effective, facile production of proteins at quantities and of quality useful for early stage drug discovery tasks such as screening and even in vivo studies.  

11:30 High-Throughput Production of Human Proteins for Structure/Function Analyses

Burgess-Brown_NicolaNicola Burgess-Brown, PhD, Principal Investigator, Nuffield Department of Medicine, SGC, University of Oxford

The SGC promotes research advancement through our open access policy. Globally, we have solved more than 2000 human protein structures and 12 novel integral membrane proteins (IMPs). Our well-established high-throughput processes for production and validation of intracellular and membrane proteins will be presented with their success rates. In addition, optimization strategies employed over the past 15 years to tackle the most recalcitrant proteins; including mutagenesis, mammalian (BacMam) expression, FSEC, and twin-step purification will be discussed.

12:00 pm Sponsored Presentation (Opportunity Available)

12:30 Session Break

12:40 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:10 Ice Cream Break in the Exhibit Hall with Poster Viewing

High-Throughput Screening

2:15 Chairperson’s Remarks

Sarah Rue, PhD, Associate Director, Advanced Automation Technologies, Genomics Institute of the Novartis Research Foundation (GNF)

2:20 DNA-Encoded Glycan Libraries as a Next-Generation Tool for Screening and Measuring Sugar Binding

Wang_Peng_GeorgePeng George Wang, PhD, Professor, Pharmacology and Chemical Biology, Baylor College of Medicine

Screening, detecting, and measuring carbohydrate-protein or carbohydrate-cell interaction/recognition is crucial to the understanding of glycan involving physiological and pathogenic processes, intervention, and regulation. Adopting DNA next-gene sequencing, we used DNA-encoded glycan library (DEGL) for high-content, high-throughput study of glycan-protein interaction. Here we will discuss novel methods designed specifically for the high-content synthesis of DNA-encoded glycans, encoding and decoding principles, selection, and sequencing approaches for the easy and universal application of DEGL for screening and measuring sugar binding.

2:50 A High-Throughput Approach for Screening Protein-Protein Interactions in Complex Biofluids Using Protein Engineering

Movileanu_LiviuLiviu Movileanu, PhD, Professor, Physics, Biomedical and Chemical Engineering, Syracuse University

Protein-protein interactions (PPIs) are at the heart of cell signaling. Yet, we have very limited ways to quantitate them, especially in a heterogeneous solution, such as blood serum. We have manufactured a single-polypeptide chain protein sensor capable of detecting transient PPIs, one interaction at a time. In this talk, I will show how a parallel electrical recording technology can be used for assessing this protein sensor in a scalable fashion.

3:20 Networking Refreshment Break

High-Throughput Antibody Processes

3:45 Application of a High-Throughput Antibody Optimization Platform: From NGS-Supported Library Generation to High-Throughput Antibody Expression and Multi-Parameter Characterization of Large Variant Libraries

Weber_ErnstErnst Weber, PhD, Laboratory Head, Biologics Lead Optimization and Project Leader, Ophthalmology, Bayer Healthcare AG

The presentation will focus on the set-up of an HT antibody optimization platform capable of improving multiple parameters in parallel. It will cover the NGS-supported generation of 1-10k variants, their HT expression and testing in parallel for multiple parameters, including stability, x-reactivity, affinity, potency, immunogenicity potential, etc., and will also include the IT infrastructure assembling and compiling the data. Case studies showing the capabilities and flexibility of such platform success, including the optimization of antibodies targeting GPCRs, will be presented.

4:15 Characterization of Novel and Complex Antibody Formats

Haberger_MarkusMarkus Haberger, Group Leader, Development Characterization Analytics, Roche Diagnostics GmbH

The number of novel biotherapeutic antibody-based formats in drug development is continuously increasing. Characterization of these formats is challenging. Since established physiochemical and mass spectrometric methods show limited capabilities for characterization of product-related impurities, new analytical strategies have to be developed. Here, we present a native MS-based HT analytical approach which successfully assisted in the elucidation of size and charge variants of complex antibody formats, such as bispecific antibodies or antibody fusion proteins.

4:45 High-Throughput Production of Antibodies Using Yeast and Mammalian Cells

Nett_JuergenJürgen Nett, PhD, Director, High-Throughput Expression, Adimab, LLC

High-throughput, small-scale protein production is an essential part of the antibody discovery workflow. After isolation from a large yeast-based antibody library, we directly express large panels of full-length IgGs in 96-well and 24-well formats. Protein purification is accomplished in a plate-based format using liquid handling platforms. The same semi-automated process is also compatible with IgGs expressed in mammalian hosts. Process setup, attributes, and output will be reviewed.

5:15 Close of Day


8:00 am Registration

8:00 BuzZ Sessions with Continental Breakfast

Protein therapeutics is a fast-growing global market. As the science improves, so does the complexity of the R&D organization. Ensuring product quality plus speed to market requires insights from stakeholders working across the stages of protein science R&D. Join experts representing this PepTalk pipeline, peers, and colleagues for an interactive roundtable discussion. Topics include highlights from the week’s presentations, new technologies and strategies, challenges, and future trends.

Click here for more details


9:00 Chairperson’s Remarks

Nicola Burgess-Brown, PhD, Principal Investigator, Nuffield Department of Medicine, SGC, University of Oxford

9:05 From DNA to Protein in Under 24 Hours; A Rapid and High-Throughput Method to Produce Native Protein

Bahl_ChristopherChristopher Bahl, PhD, Head, Protein Design, Protein Design Laboratory, Institute for Protein Innovation

We have optimized a protein production pipeline that enables the automatic expression and purification of proteins in 96-well plate format. Starting from plasmid DNA, the process can be performed in under 24 hours. Our method leverages transformation and expression in Escherichia coli, autoinduction media, affinity purification using paramagnetic beads, on-bead post-translational modification and elution; and it enables proteins to be produced in user-defined buffers.

9:35 Automated Formulation Development Using a High-Throughput Approach

Eichling_SabineSabine Eichling, PhD, Head, Advanced Formulation Development, NBE Formulation Sciences, AbbVie Deutschland GmbH & Co KG

10:05 High-Throughput Cloning and IVTT Expression for Biomarker Discovery and Functional Genomics

Murugan_VelVel Murugan, PhD, MBA, Research Scientist, Virginia G. Piper Center for Personalized Diagnostics, The Biodesign Institute, Arizona State University

DNASU is a central repository for plasmid clones and collections. Currently, we store and distribute over 300,000 plasmids, including 75,000 human and mouse plasmids, full genome collections, the protein expression plasmids from the Protein Structure Initiative as the PSI: Biology Material Repository, and both small and large collections from individual researchers. We currently possess the largest collection of human full-length clones in multiple expression-ready plasmids. I will discuss HT cloning methods that we employ for generating expression clones.

10:35 Networking Coffee Break

High-Throughput Analytics

11:00 Implementing High-Throughput Purification and Analytics Processes to Accelerate Identification of Promising Biologics Therapeutics

Daniel Yoo, Scientist, Therapeutic Discovery, Biologics Optimization, Amgen, Inc.

As new and emerging biologic therapeutics rapidly increase in complexity, there is a significant need for high throughput (HT) purification and analytics processes. Here, I present our implementation of rapid processes for screening panels, advancements to our higher-throughput platforms to enable automated complex chromatography, and tools for robust, rapid protein characterization. These enhancements enable more comprehensive screening and informed lead selection decisions.

11:30 Antibody Specificity Measurement and Scoring for Targeting Protein Post-Translational Modification Sites

Cho_YongkuYongku Cho, PhD, Assistant Professor, Chemical and Biomolecular Engineering, University of Connecticut

Antibodies targeting site-specific protein post-translational modification (PTM) is an emerging category of biotherapeutics. Many antibodies claim PTM-specificity, but users have no means of comparing their specificity. Here we report a robust flow cytometry assay that enables the determination of a specificity parameter termed Φ, which measures the fraction of non-specific signal in antibody binding.

12:00 pm Conference Wrap-Up

Vincentelli_RenaudRenaud Vincentelli, PhD, Head, High-Throughput Protein Production, Structural Biology Core, Architecture et Fonction des Macromolécules Biologiques (AFMB), UMR, CNRS – Aix-Marseille University

12:30 Close of Conference

* 活動內容有可能不事先告知作更動及調整。

Choose your language